FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden 0.5 hours per response

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BLICKENSTAFF KIM D						2. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC [TNDM]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officers (size title 2007) Others (see title 2007)					
(Last) (First) (Middle) C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET						3. Date of Earliest Transaction (Month/Day/Year) 10/13/2017								X Officer (give title Other (specify below) PRESIDENT & CEO					
(Street) SAN DIEGO CA 92121 (City) (State) (Zip)					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transa Date (Month/D					saction	ction 2A. Deemed Execution Date			tion Date, Transaction Dis			of, or Be lies Acquire of (D) (Inst	5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
							, ,		Code	v	Amount	(A) or (D)	Price	Reported Transaction				Instr. 4)	
Common Stock 10/13				3/201	2017 ⁽¹⁾			P		285,70	00 A	\$3.5	486,4	486,494 ⁽²⁾			see ootnote ⁽³⁾		
			Table II -									, or Bend ble secu		Owned		,	,	,	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution I if any (Month/Day	ate, T	1. Transaction Code (Instr. 3)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercis. Expiration Date (Month/Day/Yea		•	7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Followin Reported	or Ownersi Form: Cally Direct (Cornding (I) (Instr.	Ownership	Beneficial Ownership ct (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares		Transact (Instr. 4)				
Series A Warrants to Purchase Common Stock	\$3.5	10/13/2017			P		285,700		10/17/20	17 1	10/17/2022	Common Stock	285,700	\$0.00	285,7	700	I	See footnote ⁽³⁾	
Series B Warrants to Purchase Common	\$3.5	10/13/2017			P		285,700		10/17/20	17 (04/17/2018	Common Stock	285,700	\$0.00	285,7	700	I	See footnote ⁽³⁾	

Explanation of Responses:

- 1. The reporting person has committed to purchase shares in connection with the Company's underwritten registered public offering of common stock.
- 2. The amount of securities beneficially owned following the reported transactions reflects the 10 for 1 reverse stock split of the Issuer's issued and outstanding common stock which was effective on October 9,
- 3. The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010

Remarks:

/s/ David Berger, Attorney-in-Fact for Kim D. Blickenstaff

10/17/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.